- GlobeNewswire•10 hours agoSanthera Receives FDA Grant in Support of its Ongoing Phase I Trial with Omigapil in Congenital Muscular Dystrophy
Liestal, Switzerland, August 30, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the Office of Orphan Products Development (OOPD) at the US Food and Drug Administration (FDA) has granted Santhera ...
Liestal, Switzerland, August 29, 2016 - Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company, will announce the financial results for the first half-year 2016 on Tuesday, September 6, ...
- MarketWatch•2 months ago
Santhera Pharmaceuticals Holding AG shares dropped 35.09% in early morning trade Thursday after the Food and Drug Administration denied the company accelerated approval for its Duchenne muscular dystrophy ...
SANTHERA N (SANN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
|Bid||51.00 x 2800|
|Ask||51.10 x 1900|
|Day's Range||50.15 - 52.20|
|52wk Range||48.75 - 138.90|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||32,278|
|Dividend & Yield||N/A (N/A)|